A multicenter, randomized, double-blind, placebo-controlled study to evaluate the dose response of OPC-41061 in congestive heart failure patients with extracellular volume expansion

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the dose response of OPC-41061 in congestive heart failure patients with extracellular volume expansion

Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Tolvaptan (Primary) ; Furosemide
  • Indications Heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 17 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top